Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xilio Therapeutics ( (XLO) ) has issued an announcement.
On September 9, 2025, Xilio Therapeutics announced the initiation of Phase 2 of its clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy for advanced solid tumors. This milestone, achieved under a license agreement with Gilead Sciences, also included a $17.5 million development milestone, extending Xilio’s cash runway into early 2027. The Phase 1 trial data showed promising anti-tumor activity and a well-tolerated safety profile, supporting further clinical validation of Xilio’s proprietary technology.
The most recent analyst rating on (XLO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients without the systemic side effects of current treatments. The company leverages its proprietary platform to advance a pipeline of novel, tumor-activated molecules designed to optimize therapeutic efficacy within the tumor microenvironment.
Average Trading Volume: 405,821
Technical Sentiment Signal: Sell
Current Market Cap: $36.27M
Find detailed analytics on XLO stock on TipRanks’ Stock Analysis page.